Homelife sciences

life sciences

BioLineRx to Participate in the 12th Annual LifeSci Partners Corporate Access Event

BioLineRx to Participate in the 12th Annual LifeSci Partners Corporate Access Event

November 28, 2022

SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Eiger BioPharmaceuticals, Inc., of Class Action Lawsuit and Upcoming Deadline – EIGR

SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Eiger BioPharmaceuticals, Inc., of Class Action Lawsuit and Upcoming Deadline – EIGR

November 28, 2022

Editas (EDIT) Declines More Than 30% in 3 Months: Here’s Why

Editas (EDIT) Declines More Than 30% in 3 Months: Here’s Why

November 28, 2022

*FINAL REMINDER* AGTC Urges Shareholders to Tender Their Shares by November 28, 2022 *FINAL REMINDER*

FINAL REMINDER AGTC Urges Shareholders to Tender Their Shares by November 28, 2022 FINAL REMINDER

November 28, 2022

ContraFect Announces ANSM Approval of Clinical Trial Application for Exebacase in Prosthetic Joint Infections

ContraFect Announces ANSM Approval of Clinical Trial Application for Exebacase in Prosthetic Joint Infections

November 28, 2022

Galectin Therapeutics to Present at 6th Obesity & NASH Drug Development Summit

Galectin Therapeutics to Present at 6th Obesity & NASH Drug Development Summit

November 28, 2022

Cidara Therapeutics and Melinta Therapeutics Announce Publication of Data from the Global Phase 3 Pivotal ReSTORE Trial of Rezafungin for the Treatment of Candidemia and Invasive Candidiasis in The Lancet

Cidara Therapeutics and Melinta Therapeutics Announce Publication of Data from the Global Phase 3 Pivotal ReSTORE Trial of Rezafungin for the Treatment of Candidemia and Invasive Candidiasis in The Lancet

November 28, 2022

Nabriva Therapeutics Announces Positive Topline Results from Phase 1 Trial of XENLETA® (lefamulin) in Adult Patients with Cystic Fibrosis

Nabriva Therapeutics Announces Positive Topline Results from Phase 1 Trial of XENLETA® (lefamulin) in Adult Patients with Cystic Fibrosis

November 28, 2022

Anavex Life Sciences Reports Fiscal 2022 Year End Financial Results and Provides Business Update

Anavex Life Sciences Reports Fiscal 2022 Year End Financial Results and Provides Business Update

November 28, 2022

Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $50,000 In Eyepoint To Contact Him Directly To Discuss Their Options

Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $50,000 In Eyepoint To Contact Him Directly To Discuss Their Options

November 27, 2022

« 1 … 25 26 27 28 29 … 557 »